A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma

Cancer Chemotherapy and Pharmacology
Ji Eun UhmHo Yeong Lim

Abstract

We designed a phase II trial of the combination with oxaliplatin and doxorubicin for patients with unresectable HCC to evaluate the overall response rate (ORR) and the toxicity. Forty patients with inoperable, systemic chemotherapy naive HCC were enrolled. Finally, 32 patients received oxaliplatin (130 mg/m(2)) and doxorubicin (60 mg/m(2)) every 3 weeks. Eighty-two treatment cycles were administered (median 2 cycles, range 1-6). There was no treatment-related mortality. The ORR was 15.6% (95% CI, 3.3-28.7) with five partial responses. The median overall survival and median overall progression free survival were 31 weeks (95% CI, 22-40 weeks) and 12 weeks (95% CI, 5-19 weeks). Nausea and peripheral neuropathy were most frequent non-hematologic toxicities (nausea, n = 15; peripheral neuropathy, n = 10). The most frequent grade 3-4 hematologic adverse event was neutropenia (14 of 82 cycles) including three cases of febrile neutropenia. The combination of oxaliplatin and doxorubicin showed modest activity and a tolerable toxicity profile in advanced HCC patients.

References

May 13, 1978·Lancet·P J JohnsonI M Murray-Lyon
Jan 1, 1990·Cancer Chemotherapy and Pharmacology·J M ExtraM Marty
Feb 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R G SimonettiL Pagliaro
Apr 27, 1999·Lancet·D F Schafer, M F Sorrell
Aug 11, 2000·Critical Reviews in Oncology/hematology·J L MissetE Cvitkovic
Jun 16, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Anna K NowakMichael Findlay
Jul 13, 2004·Cancer Chemotherapy and Pharmacology·Jeeyun LeeKeunchil Park
Apr 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew X ZhuKeith Stuart
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ghassan K Abou-AlfaLeonard B Saltz
Sep 19, 2007·British Journal of Cancer·V BoigeUNKNOWN Fédération Francophone de Cancérologie Digestive
Apr 1, 2002·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Jong Myon BaeJae Gahb Park

❮ Previous
Next ❯

Citations

May 27, 2014·Clinical Oncology : a Journal of the Royal College of Radiologists·F PetrelliS Barni
Jan 8, 2013·Medical Oncology·Ji-Wen Cheng, Yi Lv
May 18, 2011·Cardiovascular and Interventional Radiology·Shobu WatanabeKiyoshi Murata
Sep 29, 2009·Expert Opinion on Investigational Drugs·Zheng WangZhi Dai
Feb 18, 2016·Chinese Medical Journal·Jia-Cheng TangXiu-Jun Cai
Nov 1, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Austin DuffyTim F Greten
Feb 11, 2015·Journal of Hepatology·Sandra M EhrlichAngelika M Vollmar
Nov 12, 2013·Journal of the Egyptian National Cancer Institute·Omar Abdel-Rahman
Apr 26, 2014·Oncology Letters·Zhanggui WangHongming Pan
Aug 10, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhen-Bin DingJia Fan
Jun 25, 2010·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Lorenza Rimassa, Armando Santoro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.